A. Luetkemeyer

发表

CROI 2019: highlights of viral hepatitis.

A. Luetkemeyer, D. Wyles, 2019, Topics in antiviral medicine.

Remdesivir for the Treatment of Covid-19 — Final Report

L. Dodd, R. Paredes, H. Lane, 2020, The New England journal of medicine.

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

P. Sax, C. Stedman, D. Dieterich, 2015, The New England journal of medicine.

Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells

D. Havlir, R. Koup, M. Leal, 2016, PloS one.

Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome

A. Luetkemeyer, H. Chambers, C. Marquez, 2017, Open forum infectious diseases.

Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings.

D. Alland, D. Havlir, S. Swindells, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2

C. Tural, A. Lazzarin, J. Rockstroh, 2017, Open forum infectious diseases.

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

D. Dieterich, S. Henn, M. Ramgopal, 2015, The New England journal of medicine.

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

John L. Johnson, S. Swindells, P. Nahid, 2011, American journal of respiratory and critical care medicine.

Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing

Erika K Wallender, F. Aweeka, A. Luetkemeyer, 2020, Clinical pharmacology and therapeutics.

Tuberculosis drug development: ensuring people living with HIV are not left behind.

D. Havlir, A. Luetkemeyer, H. Getahun, 2011, American journal of respiratory and critical care medicine.

Clinical presentation and course of acute hepatitis C infection in HIV-infected patients.

C. B. Hare, D. Havlir, P. Tien, 2006, Journal of acquired immune deficiency syndromes.

CROI 2016: Viral Hepatitis and Liver Fibrosis.

A. Luetkemeyer, D. Wyles, 2016, Topics in antiviral medicine.

The HCV Cascade of Care and Improving Access to HCV Treatment

A. Luetkemeyer, D. Wyles, 2016 .

HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era.

M. Shumway, A. Luetkemeyer, M. Peters, 2019, Journal of public health.

Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens.

A. Luetkemeyer, D. Wyles, 2017, Topics in antiviral medicine.

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

E. Daar, K. Workowski, B. Doehle, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir‐experienced, NS5A treatment‐naïve patients: Findings from two randomized trials

R. Haubrich, Minhee Kang, P. Ghali, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Handling Editor: Janus Ong Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir- experienced, NS5A treatment-naive patients: findings from two randomized trials

R. Haubrich, Minhee Kang, P. Ghali, 2017 .

NS 5 A treatment-naive patients : findings from two randomized trials

R. Haubrich, Minhee Kang, P. Ghali, 2017 .

Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.

A. Lazzarin, B. Conway, A. Luetkemeyer, 2017, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

K. Mounzer, D. Dieterich, D. Asmuth, 2014, JAMA.

Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences

M. Shumway, A. Luetkemeyer, M. Peters, 2019, AIDS care.

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens

M. Ramgopal, A. Luetkemeyer, R. Bhore, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

D. Havlir, D. Haas, S. Rosenkranz, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Complications of HIV disease and antiretroviral therapy.

D. Havlir, J. Currier, A. Luetkemeyer, 2011, Topics in antiviral medicine.

Antiretroviral therapy and TB

S. Swaminathan, D. Havlir, E. Charlebois, 2006, Tropical doctor.

Pilot Study of Pioglitazone Before HCV Retreatment in HIV/HCV Genotype 1–Infected Subjects With Insulin Resistance and Previous Nonresponse to Peginterferon and Ribavirin Therapy: A5239

P. Tien, R. Chung, D. Kitch, 2014, Journal of acquired immune deficiency syndromes.

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Cameron R. Wolfe, A. Amin, M. Proschan, 2020, The New England journal of medicine.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How?

M. Matthay, A. Luetkemeyer, 2021, JAMA.

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial

Michael R. Wierzbicki, Tom M. Conrad, Cameron R. Wolfe, 2021, The Lancet Respiratory Medicine.

Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non‐adherence

A. Luetkemeyer, D. Wyles, M. Sulkowski, 2020, Alimentary pharmacology & therapeutics.

Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification

M. Ohliger, B. Cookson, G. Borgo, 2015, Journal of Clinical Microbiology.

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

J. Rockstroh, C. Orkin, S. Bhagani, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections

J. Kaldor, J. Klausner, B. Haire, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of an Interferon-γ Release Assay with Tuberculin Skin Testing in HIV-infected Individuals

Jeffrey N. Martin, D. Havlir, D. Bangsberg, 2007 .

Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals.

Jeffrey N. Martin, D. Havlir, D. Bangsberg, 2007, American journal of respiratory and critical care medicine.

CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy.

D. Havlir, J. Currier, A. Luetkemeyer, 2013, Topics in antiviral medicine.

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Catharine I Paules, R. Hyzy, M. Proschan, 2022, The Lancet Respiratory Medicine.

SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses

Michael John Smith, E. Walsh, A. Falsey, 2022, medRxiv.

Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda

D. Havlir, G. Dorsey, M. Kamya, 2016, The Pediatric infectious disease journal.

CROI 2018: Highlights of Viral Hepatitis.

A. Luetkemeyer, D. Wyles, 2018, Topics in antiviral medicine.

Resistance Patterns and Response to Entecavir Intensification Among HIV-HBV–Coinfected Adults With Persistent HBV Viremia

C. B. Hare, D. Havlir, E. Charlebois, 2011, Journal of acquired immune deficiency syndromes.

LP01 : Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: The ALLY-2 study

D. Dieterich, A. Luetkemeyer, D. Wyles, 2015 .

Willing and able? Provision of medication for abortion by future internists.

E. Schwarz, A. Luetkemeyer, F. Stewart, 2005, Women's health issues : official publication of the Jacobs Institute of Women's Health.

HIV-Associated Central Nervous System Tuberculosis

A. Luetkemeyer, G. Chamie, C. Marquez, 2014, Seminars in Neurology.

Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.

D. Havlir, S. Swindells, F. Aweeka, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.

Lerato Mohapi, Ian Sanne, Peter Mugyenyi, 2011, The New England journal of medicine.

CROI 2015: Highlights of Viral Hepatitis Therapy.

A. Luetkemeyer, D. Wyles, 2015, Topics in antiviral medicine.

CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy.

D. Havlir, J. Currier, A. Luetkemeyer, 2014, Topics in antiviral medicine.

Overview of Hepatitis C Virus Direct-Acting Antiviral Drugs : Present and Future

D. Havlir, J. Currier, A. Luetkemeyer, 2014 .

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

B. Conway, F. Altice, G. Dore, 2017 .

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

D. Nickle, B. Conway, F. Altice, 2016, Annals of internal medicine.

Tuberculosis Associated with HIV Infection

P. Small, A. Luetkemeyer, M. Kato-Maeda, 2011 .

Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin

K. Dooley, J. Park, D. Haas, 2014, Antimicrobial Agents and Chemotherapy.

Localized US Efforts to Eliminate Hepatitis C.

A. Luetkemeyer, S. Facente, Emalie Huriaux, 2018, Infectious disease clinics of North America.

Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial.

J. Ward, M. Heo, L. Taylor, 2022, The lancet. Gastroenterology & hepatology.

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study

E. Daar, K. Workowski, B. Doehle, 2016 .

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection

A. Luetkemeyer, P. Saberi, Janet Grochowski, 2018, Integrated pharmacy research & practice.

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

M. Hughes, R. Chung, D. Fierer, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tuberculosis as part of the natural history of HIV infection in developing countries.

D. Havlir, E. Charlebois, A. Luetkemeyer, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome

D. Havlir, Kristofor J. Webb, J. Belisle, 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Tuberculosis Immune Reconstitution Inflammatory Syndrome in A5221 STRIDE: Timing, Severity, and Implications for HIV–TB Programs

D. Havlir, S. Swindells, C. Benson, 2014, Journal of acquired immune deficiency syndromes.

Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

E. Asante-Appiah, B. Conway, F. Altice, 2022, Annals of Internal Medicine.

Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated

A. M. Stanley, A. Falsey, M. Robb, 2023, Frontiers in Immunology.

Doxycycline for Sexually Transmitted Infection Prevention: Evolving Evidence and Implementation Perspectives

A. Luetkemeyer, C. Celum, 2021, Sexually transmitted diseases.

Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19

L. Pirofski, E. Antman, T. Tarpey, 2022, JAMA network open.

Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital

D. Schillinger, M. Handley, A. Cattamanchi, 2018, JAMA internal medicine.

Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis

D. Alland, I. Sanne, G. Mazurek, 2017, Journal of clinical medicine.

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

D. Ward, P. Sax, Y. Yazdanpanah, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

B. Conway, F. Altice, G. Dore, 2016 .

Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma

L. Pirofski, E. Antman, T. Tarpey, 2022, JAMA network open.

Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019

D. Glidden, G. Simmons, A. Luetkemeyer, 2021, Open forum infectious diseases.

Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata.

D. Havlir, E. Charlebois, A. Luetkemeyer, 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection

D. Clifford, N. Frahm, J. McElrath, 2016, Journal of acquired immune deficiency syndromes.

Evaluation of Two Line Probe Assays for Rapid Detection of Mycobacterium tuberculosis, Tuberculosis (TB) Drug Resistance, and Non-TB Mycobacteria in HIV-Infected Individuals with Suspected TB

D. Havlir, S. Swindells, I. Sanne, 2014, Journal of Clinical Microbiology.

Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States.

A. Luetkemeyer, 2010, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

A. Falsey, D. Montefiori, S. Little, 2023, medRxiv.

Retrospective‐prospective study of safety and efficacy of sofosbuvir‐based direct‐acting antivirals in HIV/HCV‐coinfected participants with decompensated liver disease pre– or post–liver transplant

H. Masur, J. Emond, K. Olthoff, 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence

D. Nelson, J. Dillon, A. Luetkemeyer, 2021, The American journal of gastroenterology.

Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve to HCV Therapy: Results of the ACTG A5269 Trial

V. Johnson, D. Haas, Minhee Kang, 2013, HIV clinical trials.

Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial

A. Falsey, D. Montefiori, S. Little, 2023, Research square.

B. Conway, F. Altice, E. Gane, 2022, Journal of addictive diseases.

A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries

Christopher Lane, S. Swindells, B. Metchock, 2016, BMC Infectious Diseases.

pilot metabolomics study of immune reconstitution inflammatory syndrome.

Marisa, Kristofor J. Webb, J. Belisle, 2019 .

Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure

S. Zeuzem, H. Wedemeyer, E. Gane, 2017, Hepatology.

Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections.

E. Vittinghoff, S. Buchbinder, D. Havlir, 2023, The New England journal of medicine.

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.

A. Falsey, D. Montefiori, S. Little, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

K. Schmader, E. Walsh, A. Falsey, 2023, Nature Medicine.

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

D. Havlir, D. Haas, S. Rosenkranz, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

901d Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study

D. Dieterich, A. Luetkemeyer, D. Wyles, 2015 .

CROI 2021: Viral Hepatitis and Other Forms of Liver Injury Impacting People with HIV.

A. Luetkemeyer, D. Wyles, 2021, Topics in antiviral medicine.